Regulators and lawmakers have expressed concern over possible privacy breaches as Google and Ascension collect healthcare data; Amarin’s Vascepa goes before an FDA committee this week; CMS Administrator Seema Verma defends Medicaid work requirements.
Regulators and lawmakers have expressed concern over possible privacy breaches, according to The Wall Street Journal, as Google works with Ascension to collect health information on 50 million American patients. They are calling for both additional government oversight and a temporary halt to the program. Meanwhile, Google and Ascension claim the data collection is meant to improve healthcare, and a Google spokeswoman says nothing the company gathers will be used to sell ads.
With potential sales of $3.2 billion by 2030 on the line, an FDA report gave a largely positive review to Amarin’s Vascepa ahead of its advisory committee meeting Thursday. However, as Amarin tries to expand the label for its fish oil—derived drug—first approved for use in the United States in 2012 to lower high triglyceride levels—to include that it reduces heart attacks and strokes in patients with cardiovascular disease, some experts claim trial results are skewed, Reuters reported. They believe that using mineral oil as the drug trial’s placebo worsened cholesterol levels in patients or affected the absorption of the statins they were on, tilting results in Vascepa’s favor.
On the same day CMS Administrator Seema Verma sharply defended the administration’s controversial work requirement rules forcing some Medicaid beneficiaries to work—a policy that led to thousands losing health insurance in Arkansas—the department also announced it would tighten the so-called supplemental payments to states for extra Medicaid funding for hospitals, nursing homes, and doctors. The US government spent about $48.5 billion on these payments in 2016, Kaiser Health News reported. Speaking before the National Association of Medicaid Directors in Washington, DC, Verma said that states and providers must be more transparent in how they spend the funds.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight
March 8th 2024The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
Read More